Ann Arbor, MI – April 23, 2024 –– Fifth Eye Inc., a provider of intuitive real-time clinical analytics, announced the issuance of a new patent that bolsters its innovative patient monitoring solution, the AHI System™. This milestone marks a significant advancement in predictive healthcare analytics, further validating Fifth Eye’s position at the forefront of medical technology.
The AHI System is a groundbreaking FDA-cleared clinical decision support software designed to continuously predict the risk of hemodynamic instability in real-time. Utilizing readily available ECG sensors, the AHI System identifies hemodynamic compensation and predicts the risk of hemodynamic instability, often hours before traditional vital signs indicate any abnormalities. This early detection provides clinicians with a crucial window of time to intervene, and an opportunity to prevent patient deterioration and save lives.
The new patent expands upon Fifth Eye’s existing intellectual property, enhancing the capabilities of the AHI System in several key areas. It enables healthcare professionals to promptly receive feedback on treatment effectiveness once initiated, allowing for adjustments based on real-time patient responses. Furthermore, subject to regulatory approval, the patent could allow AHI System to be included in the patient risk classification, automatically initiating therapeutic interventions through smart pumps, infusion systems, or automated drug delivery systems. This integration would simplify patient care and facilitate timely interventions.
“We are excited to announce this new patent, which represents a significant milestone in our mission to revolutionize patient monitoring and predictive healthcare analytics,” said Andrew Malcolmson, CEO of Fifth Eye. “This advancement underscores our commitment to innovation and the potential of the AHI System to transform clinical practice and improve patient outcomes.”
With this latest patent, Fifth Eye Inc. continues to expand the horizons of healthcare analytics, empowering clinicians with practical insights to deliver personalized, timely interventions. The company remains dedicated to advancing the field of patient monitoring and anticipates further breakthroughs in the near future.
About Fifth Eye: Fifth Eye Inc. is an Ann Arbor, Michigan-based company that develops intuitive, real-time clinical analytics based on physiologic waveforms to improve outcomes and reduce costs. The AHI System is the only FDA-cleared clinical decision support software that continuously predicts the risk of hemodynamic instability earlier than vital signs. Using real-time, continuous ECG lead II data feed, AHI automatically performs a series of advanced signal processing analyses, extracting HRV patterns that indicate a patient’s hemodynamic status. AHI System helps hospitals prevent adverse events, improve patient throughput, and better allocate valuable clinical staff resources to avoid nursing burnout. Fifth Eye’s machine-learning technology is licensed from the University of Michigan. For more information: www.FIFTHeye.com
AHI System is intended for use by healthcare professionals managing patients 18 years or older who are receiving continuous physiological monitoring with electrocardiography (ECG) in hospitals. This device is intended for adjunctive use with other physical vital sign parameters and patient information and is not intended to independently direct therapy.